Abstract:Objective: To explore the role of low-dose irisin in the browning of white adipose tissue (WAT) and activation of brown adipose tissue (BAT) in mice, and its effect on the metabolic function of diet induced obesity. Methods: A total of 22 C57/BLKS/J male mice fed with normal diet and 8 fed with high fat diet were separately divided into experimental and control group. The experimental group was given irisin (0.8 ng/g, 200 μl), while the control group was given the same volume (200 μl) of phosphate buffer saline every day for 14 consecutive days intraperitoneally. Food intake and body weight of mice were collected regularly every day. After intervention, the mice were killed and the changes of lipid content and activity in adipose tissue were detected by histopathology and immunohistochemistry. The effects of irisin at different concentrations (0, 20 and 40 nmol/L) on primary white adipocytes and brown adipocytes were evaluated by immunohistochemistry on uncoupling protein 1(UCP1). In order to further evaluate whether irisin has the function of improving metabolism, the changes of serum indexes and hepatic steatosis in mice fed with high-fat diet were monitored. Results: The primary white and brown adipocytes derived from mice were successfully cultured and identified in vitro. In NCD mice, the weight gain of mice with irisin was lower than that of control mice [(-0.78±0.98) vs (0.27±0.55) g]. Histopathology showed that the area of white adipocytes with irisin was smaller than controls [(14.78±8.44) vs (29.49±12.97) μm2] and the brown adipocytes were larger than controls [(0.92±0.35) vs (0.19±0.12) μm2] (both P<0.05), while the expression of UCP1 in both adipose tissues was significantly higher in irisin group. After irisin treatment, the levels of blood glucose [(7.18±0.41) vs (13.48±2.07) mmol/L, P<0.01]and cholesterol [(2.38±0.26) vs (3.89±0.93) mmol/L, P<0.05] were significantly lower than controls, and the content of lipid droplets in liver cells was less than controls [ (2.73±1.96)% vs (14.04±6.29) %, P<0.001]. Conclusions: Low dose irisin can promote the browning of WAT and activate BAT, reducing the body weight of mice by producing heat. Irisin can also effectively improve diet-induced obesity and related metabolic disorders in mice.

Irisin Protects Against Obesity-Related Chronic Kidney Disease by Regulating Perirenal Adipose Tissue Function in Obese Mice

Irisin Reverses Insulin Resistance in C2C12 Cells Via the P38-Mapk-pgc-1α Pathway.

Irisin ameliorates diabetic kidney disease by restoring autophagy in podocytes.

Irisin Prevents High-Fat Diet-Induced Metabolic Disorders Via Brown Adipose Tissue Activation

Irisin preserves mitochondrial integrity and function in tubular epithelial cells after ischemia-reperfusion-induced acute kidney injury

Irisin Ameliorates Muscle Atrophy by Inhibiting the Upregulation of the Ubiquitin‒Proteasome System in Chronic Kidney Disease

Effects of Irisin and Exercise on Metabolic Parameters and Reproductive Hormone Levels in High-Fat Diet-Induced Obese Female Mice

Exercise‐Induced Amelioration of Diet‐Induced Obesity and Diabetes is Not Regulated by Irisin

Effects of Irisin on Lipid in Mice and Glycolipid Metabolism in Obese Mice Induced by Diet

The role of irisin in kidney diseases

Irisin protects against vascular calcification by activating autophagy and inhibiting NLRP3-mediated vascular smooth muscle cell pyroptosis in chronic kidney disease

Irisin Alleviates Obesity-Related Spermatogenesis Dysfunction Via the Regulation of the AMPKα Signalling Pathway

Irisin Attenuates Vascular Remodeling in Hypertensive Mice Induced by Ang II by Suppressing Ca2+-dependent Endoplasmic Reticulum Stress in VSMCs.

Irisin Counteracts High Glucose and Fatty Acid-Induced Cytotoxicity by Preserving the AMPK-insulin Receptor Signaling Axis in C2C12 Myoblasts

Irisin Alleviates Pressure Overload-Induced Cardiac Hypertrophy by Inducing Protective Autophagy Via Mtor-Independent Activation of the AMPK-ULK1 Pathway.

Irisin Alleviates Cognitive Impairment by Inhibiting AhR/NF‐ κ B‐NLRP3‐Mediated Pyroptosis of Hippocampal Neurons in Chronic Kidney Disease

Low Serum Irisin Concentration is Associated with Poor Outcomes in Patients with Acute Pancreatitis and Irisin Administration Protects Against Experimental Acute Pancreatitis.

Involvement of GPX4 in Irisin's Protection Against Ischemia Reperfusion-Induced Acute Kidney Injury.

Irisin Stimulates Browning of White Adipocytes Through Mitogen-Activated Protein Kinase p38 MAP Kinase and ERK MAP Kinase Signaling

The Effect Of Irisin As A Metabolic Regulator And Its Therapeutic Potential For Obesity

Identification of irisin as a therapeutic agent that inhibits oxidative stress and fibrosis in a murine model of chronic pancreatitis.